Park Ridge, ILNCT06100289Now EnrollingIRB Ready

Ulcerative Colitis Clinical Trial in Park Ridge, IL

Access cutting-edge ulcerative colitis treatment through this phase 3 clinical trial at a research site in Park Ridge. Study-provided care at no cost to qualified participants.

Sponsored by Takeda

Quick Self-Assessment

See if you qualify for this Park Ridge location

Preparing your pre-screening questions…

Expert Care in Park Ridge

Access ulcerative colitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ulcerative colitis treatment provided free

Apply for This Park Ridge Location

Check if you qualify for this ulcerative colitis clinical trial in Park Ridge, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Park Ridge

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Park Ridge site if eligible
  4. 4Begin participation

About This Ulcerative Colitis Study in Park Ridge

The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for up to 34 weeks. During the study, participants will visit their study clinic several times.

Sponsor: Takeda

Who Can Participate

Inclusion Criteria

The participant weighs ≥10 kg at the time of screening and enrollment into the study.
Participants with UC or CD diagnosed at least 1 month before screening. Participants with moderately to severely active disease defined as:
Participants with UC: a modified Mayo score of 5 to 9 (sum of Mayo endoscopic subscore, stool frequency subscore, and rectal bleeding subscore) with a Mayo endoscopic subscore of ≥2 (with the presence of mucosal friability excluding an endoscopic subscore of 1 and mandating a score of at least 2). (The results of screening endoscopy should be applied.)
Participants with CD: a pediatric Crohn's disease activity index (PCDAI) \>30 and a simple endoscopic score for Crohn's disease (SES-CD) \>6 (or an SES-CD ≥4 if disease is confined to terminal ileum) at screening endoscopy.
Participants who have failed, lost response to, or been intolerant to treatment with at least 1 of the following agents: corticosteroids, immunomodulators (for example, azathioprine \[AZA\], 6-mercaptopurine \[6-MP\], methotrexate \[MTX\]), and/or tumor necrosis factor (TNF)-α antagonist therapy (for example, infliximab, adalimumab).
Participants with evidence of UC extending proximal to the rectum (that is, not limited to proctitis), at a minimum.
Participants with extensive colitis or pancolitis of \>8 years' duration or left-sided colitis of \>12 years' duration must have documented evidence of a negative surveillance colonoscopy within 12 months before screening.
Participants with vaccinations that are up-to-date based on the countrywide accepted schedule of childhood vaccines.

Exclusion Criteria

Participants who have had previous exposure to approved or investigational anti-integrins, including but not limited to, natalizumab, efalizumab, etrolizumab, or abrilumab (AMG 181); or mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antagonists (ontamalimab), or rituximab.
Participants who have had prior exposure to vedolizumab.
Participants with hypersensitivity or allergies to vedolizumab or any of its excipients.
Participants with active cerebral/meningeal disease, signs/symptoms or history of progressive multifocal leukoencephalopathy (PML) or any other major neurological disorders.
The participant has received any live vaccinations within 30 days before first dose of study drug.
Participants who currently require surgical intervention or are anticipated to require surgical intervention for UC or CD during this study.
Participants who have had subtotal or total colectomy or have a jejunostomy, ileostomy, colostomy, ileo-anal pouch, known fixed stenosis of the intestine, short bowel syndrome, or \>3 small intestine resections.
Participants with a current diagnosis of indeterminate colitis.
Participants with clinical features suggesting monogenic very early-onset inflammatory bowel disease (IBD).
Participants with active or latent tuberculosis (TB).
Participants with evidence of positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Hepatitis B virus (HBV) immune subjects (that is, HBsAg negative and hepatitis B surface antibody \[anti-HBs\]-positive) may, however, be included.
The participant has any identified congenital or acquired immunodeficiency (for example, common variable immunodeficiency, human immunodeficiency virus \[HIV\] infection, organ transplantation).
Participants with positive stool studies for ova and/or parasites or stool culture at screening visit.
Participants with positive Clostridioides difficile (C difficile) stool test at screening visit.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Park Ridge?

Yes, this clinical trial (NCT06100289) has an active research site in Park Ridge, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ulcerative Colitis Treatment Options in Park Ridge, IL

If you're searching for ulcerative colitis treatment options in Park Ridge, IL, this clinical trial (NCT06100289) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Park Ridge research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced ulcerative colitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ulcerative colitis clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Park Ridge, IL

See all rheumatoid arthritis clinical trials recruiting in Park Ridge — not just this study.

Browse Rheumatoid Arthritis Trials in Park Ridge →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsUlcerative Colitis TrialsInflammatory Bowel Disease TrialsAll Conditions →

Ready to Join in Park Ridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Park Ridge, IL